New stroke breakthroughs spotlight faster treatment, factor XI prevention, better recovery, and the push to deliver care equitably with smart wearables.
Ashkan Shoamanesh, MD, FRCPC
Advertisement
Associate professor, Division of Neurology
McMaster University in Hamilton, Canada
Articles by Ashkan Shoamanesh, MD, FRCPC
Ashkan Shoamanesh, MD, discusses a secondary analysis of the efficacy and safety of the factor XIa inhibitor asundexian by underlying stroke etiology.
Advertisement
Latest Updated Articles
Asundexian Outcomes Across Noncardioembolic Stroke Subtypes: Ashkan Shoamanesh, MD, FRCPCPublished: February 9th 2026 | Updated:
Advertisement
Advertisement
Trending on AJMC
1
Contributor: American Patients vs Foreign Governments—A Tale of 2 Value Sets
2
FDA Approves First-in-Class Optune Pax Device for Pancreatic Cancer
3
Bipartisan Break Up Big Medicine Act Targets Vertical Integration in Health Care
4
Asundexian Cuts Recurrent Stroke Risk Without More Bleeding: Mukul Sharma, MD, MSc
5